Phase 1 study of GSK3228836 pharmacokinetics in participants with hepatic impairment

Trial Identifier: 205871
Sponsor: GlaxoSmithKline
Collaborator:
N/A
Start Date: September 2021
Primary Completion Date: May 2022
Study Completion Date: May 2022
Condition: Hepatitis B

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
United States, Florida Orlando, Florida, United States, 32809
United States, Texas San Antonio, Texas, United States, 78215